Drug Trial Radar · NCT04526665
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
161
Actual
Start
Sep 24, 2020
Primary completion
Jun 1, 2023
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Aug 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver disease). PBC is a slowly progressive disease characterized by damage of the bile ducts in the liver, leading to a buildup of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. The main aim of this study is to determine if elafibranor (the study drug) is better than placebo (a dummy treatment) at decreasing the levels of a specific blood test (alkaline phosphatase) that provides information about participant's disease. This study will also evaluate the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itchy skin (pruritus) and tiredness (fatigue). This study has two main parts: Part 1 will compare a daily dose of elafibranor to a daily dose of placebo and will last between a minimum of one year and a maximum of two years. Part 2, all participants will receive elafibranor for a period of up to 5 years or until the total treatment duration (part 1 and part 2) reaches 6 years, whichever occurs first.
Conditions
- Primary Biliary Cirrhosis
Interventions
Elafibranor 80mgDrug
Elafibranor 80mg daily
PlaceboDrug
Placebo daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52Time frame: At Week 52
Locations
115 sites in 14 countries. Site status is shown where the registry gives one.
The Institute for Liver Health
Chandler, Arizona
Keck Medical Center of USC
Los Angeles, California
Ruane Clinical Research Group Inc.
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
University of California, Davis Medical Center
Sacramento, California
California Pacific Medical Center - Sutter Pacific Medical Foundation
San Francisco, California
University of Colorado Denver and Hospital
Aurora, Colorado
South Denver Gastroenterology, P.C.
Englewood, Colorado
Yale School of Medicine, Digestive Diseases
New Haven, Connecticut
Encore Borland-Groover Clinical Research
Jacksonville, Florida
Schiff Center for Liver Diseases/University of Miami
Miami, Florida
Digestive Healthcare of Georgia
Atlanta, Georgia
University of Kansas Medical Center
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts
Henry Ford Health System
Novi, Michigan
Saint Louis University
St Louis, Missouri
UPMC Center for Liver Diseases
New Hyde Park, New York
NYU Langone Health / NYU Grossman School of Medicine
New York, New York
Columbia University Medical Center - Center for Liver Disease and Transplantation
New York, New York
The New York-Presbyterian Hospital, David H. Koch Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Carolinas Centre for Liver disease/ Atrium Health
Huntersville, North Carolina
Consultants for Clinical Research
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
Investigational Drug Service Pharmacy Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
Medical University of South Carolina- College of Medicine
Charleston, South Carolina
Vanderbilt Digestive Disease Center
Nashville, Tennessee
Texas Clinical Research Institute, LLC
Arlington, Texas
The Liver Institute at Methodist Dallas Medical Center
Dallas, Texas
Liver Center of Texas, PLLC
Dallas, Texas
The University of Texas Southwestern Medical Center-IDS Aston Pharmacy
Dallas, Texas
Texas Digestive Disease Consultants dba GI Alliance
Fort Worth, Texas
Liver Associates of Texas, P.A.
Houston, Texas
St. Luke's Health-Baylor St Luke's Medical center - Advanced Liver Therapies Research
Houston, Texas
American Research Corporation
San Antonio, Texas
Gastro health & Nutrition-Victoria
Victoria, Texas
Intermountain Medical Center - Transplant Services
Murray, Utah
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.